FHTX

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the innovative development of therapies targeting genetic dependencies within the chromatin regulatory system. Leveraging its proprietary Gene Traffic Control platform, Foghorn is advancing a robust pipeline of therapeutic candidates designed to address diverse cancers and genetic disorders. The company's strategic focus on precision medicine and commitment to enhancing patient outcomes solidifies its role as a significant contender in the evolving biopharmaceutical landscape, poised to deliver transformative treatment solutions.